Streetbeat News

Analyst Ratings

DELL

Barclays analyst Tim Long has upgraded Dell Technologies from Underweight to Equal-Weight and set a price target of $97.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:32 am

FR

Wolfe Research has upgraded First Industrial Realty (NYSE:FR) from Peer Perform to Outperform, with a new price target of $64.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:25 am

ZI

Daiwa Capital has downgraded ZoomInfo Technologies (NASDAQ:ZI) from Outperform to Neutral and lowered the price target from $15 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:21 am

THG

Keefe, Bruyette & Woods analyst Meyer Shields maintains a Market Perform rating on Hanover Insurance Group (NYSE:THG) and raises the price target from $142 to $144.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:17 am

AAPL

Apple Inc. (NASDAQ:AAPL) is rumored to be working on a thinner version of the iPhone 17, called the 'Air,' expected to launch in 2025. This model could potentially drive significant growth for the company. Gene Munster and other analysts are optimistic about the impact of this design change on iPhone sales. However, Apple's previous attempts to change the iPhone's size did not yield significant results. The iPhone 16, set to launch next month, will focus on Apple Intelligence features rather than a radical redesign.

Portfolio Pulse from Benzinga Neuro

August 13, 2024 | 10:13 am

RNA

Needham analyst Joseph Stringer reiterates a Buy rating on Avidity Biosciences (NASDAQ:RNA) and maintains a $60 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:11 am

RVNC

Needham analyst Serge Belanger has downgraded Revance Therapeutics (NASDAQ:RVNC) from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:08 am

ORIC

Oppenheimer analyst Matthew Biegler maintains an Outperform rating on ORIC Pharmaceuticals (NASDAQ:ORIC) but lowers the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:06 am

LUCD

Needham analyst Mike Matson has reiterated a Buy rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:05 am

ESPR

Needham analyst Serge Belanger maintains a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) but lowers the price target from $8 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:02 am